CytoSorbents Q2 revenue $9.4M (+11% YoY); STAR-T trial enrollment complete

Cytosorbents Corp

2023-Q2 EPS reported -$0.31 revenue$18,870,317

Product sales rose 10% to $8.1M; product gross margins improved 700 bps to 74%.
STAR-T pivotal trial for DrugSorb-ATR completed enrollment ahead of schedule; DSMB recommended completion.
Quarterly cash burn reduced to ~$4.5M in H1 2023 from ~$11M in H1 2022.
Appointed Alexander D'Amico as CFO effective August 7, 2023; Michael Bator named Chairman.
Cash and restricted cash totaled $14.8M as of June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported the quarter ended June 30, 2023 results: revenue $9.4 million.

Period: the quarter ended June 30, 2023
Revenue: $9.4 million
Result: reported results

Exact text from the filing

Q2 2023 Total Revenue was $9.4 million, an 11% increase from $8.5 million in Q2 2022.

View on SEC.gov

Browse all earnings releases →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-086470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.